Metoprolol Succinate 47.5mg ER Tablets

Metoprolol Succinate 47.5mg is a prolonged-release beta blocker used for high blood pressure, angina and selected stable heart-failure regimens. It reduces heart rate and myocardial workload throughout the dosing interval.
Take with or immediately after a meal at a consistent time. Swallow the prolonged-release tablet without crushing or chewing. Any permitted splitting depends on the scored product design. Reduce gradually when stopping rather than withdrawing abruptly.
Metoprolol preferentially blocks beta-1 adrenergic receptors in the heart, reducing heart rate, contraction strength and renin release. Prolonged release spreads delivery over time.
Fatigue, dizziness, slow pulse, low blood pressure and cold extremities may occur. Fainting, worsening fluid retention or severe wheezing needs prompt assessment.
Heart block, marked bradycardia and unstable decompensated heart failure are important risks. Asthma and diabetes require attention. Verapamil, diltiazem, digoxin and other rate-slowing medicines can add to bradycardia. CYP2D6 inhibitors can increase exposure.
Provides sustained reduction in cardiac adrenergic workload and helps control pressure or angina when a beta blocker is appropriate.
Not by tablet count alone. Succinate prolonged-release and immediate-release products can have different schedules and strength-expression conventions.
Crushing disrupts the prolonged-release design and can alter delivery of the full dose.
Yes. Beta blockade blunts the usual heart-rate rise, so exercise targets may need to use symptoms or perceived exertion rather than pulse alone.
It can reduce warning signs such as palpitations; sweating or neuroglycopenic symptoms may still occur.
Sudden loss of beta blockade can increase sympathetic activity and provoke rebound angina or more serious cardiac events.
Beta blocker: a medicine reducing adrenergic receptor activity. Myocardium: heart muscle. Angina: chest discomfort caused by inadequate heart-muscle blood flow. CYP2D6: an enzyme involved in metoprolol metabolism; AR: Metoprolol Succinate 47.5mg أقراص ممتدة التحرر; FR: Metoprolol Succinate 47.5mg comprimés à libération prolongée; PT: Metoprolol Succinate 47.5mg comprimidos de libertação prolongada; ES: Metoprolol Succinate 47.5mg comprimidos de liberación prolongada; RU: Metoprolol Succinate 47.5mg таблетки пролонгированного высвобождения; ID: Metoprolol Succinate 47.5mg tablet lepas lambat; VI: Metoprolol Succinate 47.5mg viên nén giải phóng kéo dài; MS: Metoprolol Succinate 47.5mg tablet pelepasan berpanjangan; TL: Metoprolol Succinate 47.5mg tabletang may pinalawig na paglabas; ZH-SG: Metoprolol Succinate 47.5mg 缓释片
International B2B Enquiry
Send a structured B2B enquiry for Metoprolol Succinate 47.5mg ER Tablets under Cardiac Care. Global Medicines Export helps international buyers review product information, pack details, quantity requirements, destination-market needs, quotation support and export documentation coordination from India.
Product name, required strength or pack, expected quantity, destination country, buyer type and preferred manufacturer if any.
Availability, quotation support, documentation expectations and shipment-ready order communication can be reviewed before confirmation.
Commercial invoice, packing information, manufacturer details, batch details and supporting documents where applicable and available.
Product availability, quotation, and documentation support are coordinated for international B2B enquiries.
Metoprolol Succinate 47.5mg ER Tablets